Identification

Name
Iron Dextran
Accession Number
DB00893
Description

Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible.

Type
Small Molecule
Groups
Approved, Vet approved
Synonyms
  • Dextran iron
  • Iron dextran complex

Pharmacology

Indication

For treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Also used to replenish body iron stores in Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) patients receiving or not receiving erythropoietin and in Hemodialysis Dependent (HDD-CKD) and Peritoneal Dialysis Dependent (PDD-CKD) - Chronic Kidney Disease patients receiving an erythropoietin.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Iron dextran is a dark brown, slightly viscous sterile liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. It is for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Iron is essential to the formation of hemoglobin and to the function and formation of other heme and nonheme compounds. Untreated depletion of iron stores leads to iron-deficient erythropoiesis and, in turn, to iron deficiency anemia.

Mechanism of action

After iron dextran is injected, the circulating iron dextran is removed from the plasma by cells of the reticuloendothelial system, which split the complex into its components of iron and dextran. The iron is immediately bound to the available protein moieties to form hemosiderin or ferritin, the physiological forms of iron, or to a lesser extent to transferrin. This iron which is subject to physiological control replenishes hemoglobin and depleted iron stores.

TargetActionsOrganism
AHemoglobin subunit beta
activator
Humans
AHemoglobin subunit alpha
activator
Humans
AFerritin heavy chain
other
Humans
AFerritin light chain
other
Humans
Absorption

The major portion of intramuscular injections of iron dextran is absorbed within 72 hours; most of the remaining iron is absorbed over the ensuing 3 to 4 weeks.

Volume of distribution
Not Available
Protein binding

100% (after release from dextran)

Metabolism

Dextran, a polyglucose, is either metabolized or excreted.

Route of elimination

Dextran, a polyglucose, is either metabolized or excreted.

Half-life

5 hours (some indications that it can be as long as 10 hours)

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

LD50 = 500 mg/kg (mouse, IV). Dosages of iron dextran in excess of the requirements for restoration of hemoglobin and replenishment of iron stores may lead to hemosiderosis. Cases of severe, sometimes fatal, allergic reactions (loss of consciousness, collapse, difficulty breathing, hives, swelling, or convulsions) and severe low blood pressure (hypotension) have been reported with the use of iron dextran.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AlmasilateAlmasilate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
AluminiumAluminium can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium phosphateAluminium phosphate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Iron Dextran.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium PhosphateIron Dextran can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium phosphate dihydrateIron Dextran can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Iron Dextran.
CarbidopaIron Dextran can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Active Moieties
NameKindUNIICASInChI Key
IronunknownE1UOL152H77439-89-6XEEYBQQBJWHFJM-UHFFFAOYSA-N
Ferric cationionic91O4LML61120074-52-6VTLYFUHAOXGGBS-UHFFFAOYSA-N
Product Images
International/Other Brands
CosmoFer (B. Braun) / Feosol (GlaxoSmithKline) / Imferon (Sanofi-Aventis) / Proferdex (New River Pharmaceuticals Inc.)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
DexferrumInjection, solution50 mg/1mLIntravenousAMERICAN REGENT, INC.1998-10-012013-04-22Us
DexferrumInjection, solution50 mg/1mLIntravenousAMERICAN REGENT, INC.1996-03-012013-04-08Us
INFeDInjection50 mg/1mLIntramuscular; IntravenousActavis Pharma, Inc.1974-04-292021-08-31Us
InfedInjection, solution50 mg/1mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2010-09-012021-08-31Us
INFeDInjection50 mg/1mLIntramuscular; IntravenousAllergan, Inc.1974-04-29Not applicableUs
InfedInjection50 mg/1mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc.2019-01-21Not applicableUs
Iron DextranInjection50 mg/1mLIntramuscular; IntravenousHF Acquisition Co LLC, DBA HealthFirst2019-12-22Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
BiferaRxIron Dextran (22 mg/1) + Cyanocobalamin (25 ug/1) + Folic acid (1 mg/1) + Heme iron polypeptide (6 mg/1)TabletOralAlaven Pharmaceutical LLC2010-05-012019-09-30Us68220 0085 90 nlmimage10 2d1316d8
BiferaRxIron Dextran (22 mg/1) + Cyanocobalamin (25 ug/1) + Folic acid (1 mg/1) + Heme iron polypeptide (6 mg/1)TabletOralMEDA Pharmaceuticals2012-10-312018-09-30Us
Iron Polysaccharides Folic Acid DHAIron Dextran (29 mg/1) + Ascorbic acid (30 mg/1) + Beta carotene (1100 [iU]/1) + Cholecalciferol (1000 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + DL-alpha tocopheryl acetate (20 mg/1) + Doconexent (200 mg/1) + Folic acid (1 mg/1) + Magnesium oxide (20 mg/1) + Nicotinamide (15 mg/1) + Potassium Iodide (150 ug/1) + Pyridoxine hydrochloride (2.5 mg/1) + Riboflavin (1.8 mg/1) + Thiamine mononitrate (1.6 mg/1) + Zinc oxide (25 mg/1)Tablet, film coatedOralVirtus Pharmaceuticals2013-12-202013-12-30Us
Irospan 24/6Iron Dextran (65 mg/1) + Biotin (300 ug/1) + Biotin (300 ug/1) + Calcium carbonate (100 mg/1) + Cyanocobalamin (10 ug/1) + Cyanocobalamin (10 ug/1) + Ferrous bisglycinate (65 mg/1) + Folic acid (1 mg/1) + Folic acid (1 mg/1) + Calcium formate (155 mg/1) + Niacin (25 mg/1) + Niacin (25 mg/1) + Calcium pantothenate (300 ug/1) + Calcium pantothenate (7 mg/1) + Pyridoxine hydrochloride (30 mg/1) + Pyridoxine hydrochloride (30 mg/1) + Riboflavin sodium (5 mg/1) + Riboflavin (5 mg/1) + Sodium ascorbate (100 mg/1) + Sodium ascorbate (100 mg/1) + Succinic acid (150 mg/1) + Thiamine hydrochloride (5 mg/1) + Thiamine hydrochloride (5 mg/1)OralWOMENS CHOICE PHARMACEUTICALS LLC2011-04-15Not applicableUs
NiferexIron Dextran (100 mg/1) + Ascorbic acid (60 mg/1) + Cyanocobalamin (25 ug/1) + Ferrous asparto glycinate (50 mg/1) + Folic acid (250 ug/1) + Gastric intrinsic factor (100 mg/1) + Levomefolic acid (750 ug/1) + Succinic acid (50 mg/1) + Zinc (15 mg/1)TabletOralAvion Pharmaceuticals, Llc2017-01-10Not applicableUs
Prefera OB plus DHAIron Dextran (22 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate pentahydrate (0.8 mg/1) + Cyanocobalamin (12 ug/1) + Folic acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (175 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.6 mg/1) + Selenium (65 ug/1) + Thiamine mononitrate (1.5 mg/1) + Zinc oxide (15 mg/1) + alpha-Tocopherol succinate (10 [iU]/1)TabletOralAlaven Pharmaceutical LLC2009-04-012019-01-01Us
PreferaOBIron Dextran (28 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate pentahydrate (0.8 mg/1) + Cyanocobalamin (12 ug/1) + Folic acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (250 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.6 mg/1) + Selenium (65 ug/1) + Thiamine mononitrate (1.5 mg/1) + Zinc oxide (4.5 ug/1) + alpha-Tocopherol succinate (10 [iU]/1)TabletOralAlaven Pharmaceutical LLC2010-09-272019-01-01Us
PreferaOB OneIron Dextran (22 mg/1) + Ascorbic acid (25 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cyanocobalamin (12 ug/1) + DL-alpha tocopheryl acetate (10 [iU]/1) + Doconexent (200 mg/1) + Folic acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (175 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Zinc oxide (15 ug/1)CapsuleOralAlaven Pharmaceutical LLC2010-04-012019-01-01Us
PreferaOB plus DHAIron Dextran (28 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate pentahydrate (0.8 mg/1) + Cyanocobalamin (12 ug/1) + Folic acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (250 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.6 mg/1) + Selenium (65 ug/1) + Thiamine mononitrate (1.5 mg/1) + Zinc oxide (4.5 ug/1) + alpha-Tocopherol succinate (10 [iU]/1)TabletOralAlaven Pharmaceutical LLC2010-11-152019-01-01Us
PureFe OB PlusIron Dextran (53 mg/1) + Cupric sulfate pentahydrate (0.8 mg/1) + Cyanocobalamin (15 ug/1) + Ferrous fumarate (53 mg/1) + Folic acid (1 mg/1) + Magnesium sulfate (6.9 mg/1) + Manganese sulfate (1.3 mg/1) + Nicotinamide (30 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (5 mg/1) + Riboflavin (6 mg/1) + Sodium ascorbate (200 mg/1) + Thiamine mononitrate (10 mg/1) + Zinc sulfate, unspecified form (18.2 mg/1)CapsuleOralPureTek Corporation2011-06-012019-05-28Us

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
95HR524N2M
CAS number
9004-66-4
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

Synthesis Reference

William T. Monte, Laurie Scaggs, "Process for making crystalline iron dextran." U.S. Patent US5756715, issued 1905.

US5756715
General References
  1. Iron dextran FDA LABEL [Link]
KEGG Drug
D02141
PubChem Substance
46506136
RxNav
5992
ChEMBL
CHEMBL1201544
Therapeutic Targets Database
DAP001312
PharmGKB
PA164764618
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Iron_Dextran
MSDS
Download (45.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentIron Deficiency Anemia of Pregnancy / Iron Malabsorption1
4CompletedTreatmentTreatment of Iron Deficiency Anemia in Pregnancy1
4Not Yet RecruitingTreatmentChemotherapy-induced Anaemia1
4SuspendedTreatmentIron Deficiency Anemia (IDA) / Perioperative Blood Conservation1
4TerminatedTreatmentAnemia1
3CompletedTreatmentAnemia2
3Not Yet RecruitingTreatmentIron Deficiency / Iron Deficiency Anemia (IDA) / Iron-Deficiency1
2CompletedTreatmentAnemia / Non-Myeloid Malignancies1
2CompletedTreatmentIron Deficiency Anemia (IDA)3
2CompletedTreatmentIron Deficiency / Pulmonary Arterial Hypertension (PAH)1

Pharmacoeconomics

Manufacturers
  • Luitpold pharmaceuticals inc
  • Watson laboratories inc
  • Sanofi aventis us llc
  • New river pharmaceuticals inc
Packagers
  • Alaven Pharmaceutical
  • American Regent
  • General Injectables and Vaccines Inc.
  • Gensavis LLC
  • Luitpold Pharmaceuticals Inc.
  • Patheon Inc.
  • Physicians Total Care Inc.
  • Primedics Laboratories
  • Schein Pharmaceutical Inc.
  • Watson Pharmaceuticals
Dosage Forms
FormRouteStrength
TabletOral
Solution
Injection, solutionIntravenous50 mg/1mL
Injection
InjectionIntramuscular; Intravenous50 mg/1mL
Injection, solutionIntramuscular; Intravenous50 mg/1mL
CapsuleOral
Tablet, film coatedOral
Capsule, gelatin coatedOral
Prices
Unit descriptionCostUnit
Iron dextran comp 100 mg/2 ml38.08USD ml
Dexferrum 100 mg/2 ml vial21.6USD ml
Dexferrum 50 mg/ml vial21.6USD ml
Dexiron 50 mg/ml15.66USD ml
Infufer 50 mg/ml15.53USD ml
Infed 100 mg/2 ml vial14.44USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5624668No1997-04-292015-09-29Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Activator
General Function
Oxygen transporter activity
Specific Function
Involved in oxygen transport from the lung to the various peripheral tissues.LVV-hemorphin-7 potentiates the activity of bradykinin, causing a decrease in blood pressure.Spinorphin: functions as an...
Gene Name
HBB
Uniprot ID
P68871
Uniprot Name
Hemoglobin subunit beta
Molecular Weight
15998.34 Da
References
  1. Zaric J, Lazic D, Markovic S, Glisin V, Ivanovic Z, Milenkovic P, Popovic Z: Alpha- and beta-globins of the anemic Belgrade laboratory rat. II. The effect of hemin and iron-dextran treatment. Hemoglobin. 1998 May;22(3):231-44. [PubMed:9629498]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Activator
General Function
Oxygen transporter activity
Specific Function
Involved in oxygen transport from the lung to the various peripheral tissues.
Gene Name
HBA1
Uniprot ID
P69905
Uniprot Name
Hemoglobin subunit alpha
Molecular Weight
15257.405 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Other
General Function
Iron ion binding
Specific Function
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after ...
Gene Name
FTH1
Uniprot ID
P02794
Uniprot Name
Ferritin heavy chain
Molecular Weight
21225.47 Da
References
  1. Iron dextran FDA LABEL [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Other
General Function
Iron ion binding
Specific Function
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a ro...
Gene Name
FTL
Uniprot ID
P02792
Uniprot Name
Ferritin light chain
Molecular Weight
20019.49 Da
References
  1. Iron dextran FDA LABEL [Link]

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Transferrin receptor binding
Specific Function
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from si...
Gene Name
TF
Uniprot ID
P02787
Uniprot Name
Serotransferrin
Molecular Weight
77063.195 Da
References
  1. Macdougall IC: Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999 Mar;69:S61-6. [PubMed:10084288]
  2. Salahudeen AK, Oliver B, Bower JD, Roberts LJ 2nd: Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int. 2001 Oct;60(4):1525-31. [PubMed:11576368]
  3. Pai AB, Boyd AV, McQuade CR, Harford A, Norenberg JP, Zager PG: Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy. 2007 Mar;27(3):343-50. [PubMed:17316146]
  4. Jacobs JC, Alexander NM: Colorimetry and constant-potential coulometry determinations of transferrin-bound iron, total iron-binding capacity, and total iron in serum containing iron-dextran, with use of sodium dithionite and alumina columns. Clin Chem. 1990 Oct;36(10):1803-7. [PubMed:2208657]
  5. Speyer BE, Doney VJ, Fielding J: Transfer of iron from Ferastral and other organic complexes to transferrin as measured by reticulocyte uptake. Scand J Haematol Suppl. 1977;32:215-21. [PubMed:272031]

Drug created on June 13, 2005 07:24 / Updated on June 12, 2020 11:41

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates